Lupin Expands European Eye Care Through VISUfarma Acquisition

Lupin Limited announced on April 02, 2026, the completion of its acquisition of VISUfarma B.V., a European specialty pharmaceutical firm focused on ophthalmology. This strategic move significantly bolsters Lupin's presence and offerings in the eye care segment.

VISUfarma generated €53 million in revenue in 2025. The acquisition adds over 60 branded products to Lupin's eye care portfolio, significantly expanding its range. The deal is expected to strengthen Lupin's commercial footprint across key European markets, including Italy, the UK, Spain, Germany, and France.

Lupin, an Indian multinational pharmaceutical company, has been pursuing global expansion through targeted acquisitions, with a growing focus on specialty segments and developed markets like Europe. VISUfarma, established in 2016, was built by healthcare-focused private equity firm GHO Capital to become a pan-European leader in ophthalmology.

The acquisition is anticipated to be immediately accretive to Lupin's earnings. However, key areas to watch will include the successful integration of VISUfarma's operations and products into Lupin's global structure, and navigating the competitive ophthalmology market in Europe against established players. The combined entity aims to address the growing global demand for advanced eye care solutions.